MetLife Investment Management LLC Lowers Stock Holdings in Progyny, Inc. (NASDAQ:PGNY)

MetLife Investment Management LLC decreased its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 46.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 48,806 shares of the company's stock after selling 42,139 shares during the quarter. MetLife Investment Management LLC owned approximately 0.05% of Progyny worth $818,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PGNY. International Assets Investment Management LLC lifted its position in Progyny by 1,576.0% in the third quarter. International Assets Investment Management LLC now owns 2,565,118 shares of the company's stock valued at $42,991,000 after acquiring an additional 2,412,068 shares during the last quarter. Pacer Advisors Inc. lifted its holdings in shares of Progyny by 12,579.4% in the 3rd quarter. Pacer Advisors Inc. now owns 2,492,642 shares of the company's stock valued at $41,777,000 after purchasing an additional 2,472,983 shares during the last quarter. Farallon Capital Management LLC boosted its position in shares of Progyny by 120.8% in the 2nd quarter. Farallon Capital Management LLC now owns 1,308,500 shares of the company's stock valued at $37,436,000 after purchasing an additional 715,900 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Progyny by 24.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,281,928 shares of the company's stock valued at $36,676,000 after purchasing an additional 254,725 shares during the period. Finally, Kornitzer Capital Management Inc. KS grew its stake in Progyny by 15.7% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 976,501 shares of the company's stock worth $16,366,000 after buying an additional 132,672 shares during the last quarter. 94.93% of the stock is owned by institutional investors and hedge funds.

Progyny Stock Down 1.6 %

NASDAQ PGNY traded down $0.24 during mid-day trading on Friday, hitting $14.76. The stock had a trading volume of 850,553 shares, compared to its average volume of 1,660,780. The company has a 50 day simple moving average of $15.63 and a 200 day simple moving average of $21.79. The company has a market cap of $1.26 billion, a price-to-earnings ratio of 25.45, a P/E/G ratio of 1.72 and a beta of 1.35. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $42.08.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The company had revenue of $286.63 million during the quarter, compared to analysts' expectations of $296.85 million. During the same period in the previous year, the company posted $0.16 EPS. Progyny's quarterly revenue was up 2.0% compared to the same quarter last year. As a group, equities analysts anticipate that Progyny, Inc. will post 0.59 earnings per share for the current fiscal year.

Analyst Ratings Changes

PGNY has been the topic of a number of research reports. JPMorgan Chase & Co. restated a "neutral" rating and set a $17.00 target price (down from $22.00) on shares of Progyny in a research report on Monday, December 2nd. Leerink Partners dropped their price objective on shares of Progyny from $25.00 to $21.00 and set a "market perform" rating on the stock in a research note on Thursday, September 19th. Truist Financial reaffirmed a "hold" rating and issued a $19.00 target price (down from $26.00) on shares of Progyny in a report on Wednesday, November 13th. Bank of America lowered their price target on Progyny from $22.00 to $21.00 and set a "buy" rating on the stock in a report on Wednesday, November 13th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price objective on shares of Progyny in a research note on Tuesday, October 1st. Nine equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $25.00.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.